<DOC>
	<DOCNO>NCT01225276</DOCNO>
	<brief_summary>NewGam ( current work title new IGIV formulation ) newly develop human normal immunoglobulin solution ready intravenous administration ( IGIV ) . This study evaluate safety efficacy three different dosage NewGam 10 % patient Chronic Inflammatory Demyelinating Polyradiculoneuropathy .</brief_summary>
	<brief_title>Safety Efficacy Study Three Different Dosages NewGam Patients With CIDP</brief_title>
	<detailed_description>This Phase 2/3 study take place 2 stage . The primary objective Stage 1 ( Phase 2 dose-finding part ) determine select one dosage three NewGam maintenance dosage arm comparison placebo arm , base percentage responder ( response define decrease , mean improvement , adjust INCAT disability score least 1 point ) . The select NewGam dosage placebo employ compare Stage 2 . The primary objective Stage 2 ( Phase 3 confirmatory part ) demonstrate superiority maintenance dosage regimen select study Stage 1 placebo patient CIDP assess percentage responder . The secondary objective evaluate safety ( measured number adverse event ) efficacy NewGam administration patient CIDP compare baseline .</detailed_description>
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<criteria>Patients diagnose CIDP base fulfilment clinical criterion INCAT Group definite electrophysiological criterion CIDP ; patient MADSAM pure motor CIDP include provide fulfil criterion Worsening disability objective increase weakness sensory deficit 6 month prior screen &gt; =18 year age Unifocal form CIDP Pure sensory CIDP MMN conduction block Treatment CIDP immunoglobulin ( intravenous subcutaneous ) time prior study entry Steroids type equivalent prednisolone prednisone &gt; 10 mg/day equivalent plasma exchange ( PE ) last 3 month prior baseline visit Treatment cyclosporin , methotrexate , mitoxantrone , mycophenolate mofetil , interferon immunosuppressive immunomodulatory drug three month prior baseline visit Clinical evidence peripheral neuropathy another Known diabetes mellitus Other serious medical condition complicate assessment treatment Thromboembolic event : patient history deep vein thrombosis ( DVT ) within last year prior baseline visit pulmonary embolism ever Known IgA deficiency antibody IgA History hypersensitivity , anaphylaxis severe systemic response immunoglobulin , blood plasma derive product , component NewGam Known blood hyperviscosity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CIDP</keyword>
	<keyword>IVIG</keyword>
</DOC>